Illumina is reducing its forecast for this year’s financial performance and cutting $100 million in spending because China ...

China imposed an import ban on Illumina’s gene sequencers in response to President Trump’s escalating tariffs and trade war ...

Illumina will seek to cut $100 million in expenses by the end of this fiscal year as it plans to deal with a loss of revenue ...

Illumina slashes costs by $100 million after China bans its sequencers. The company lowers its 2025 EPS outlook and aims for ...

RBC Capital lowered the firm’s price target on Illumina (ILMN) to $128 from $247 but keeps an Outperform rating on the shares. The company’s ...

Illumina (ILMN) responded to the March 4 notice from the China Ministry of Commerce that the company is not permitted to export sequencing ...

Illumina, Inc. (Nasdaq: ILMN) ("Illumina" or the "company") today responded to the March 4, 2025 notice from the China Ministry of Commerce ("MOFCOM") that Illumina is not permitted to export ...

China accounts for about 7% of Illumina's sales. China's commerce ministry said in a statement that Illumina "violated the ...

In a sign it is willing to go further in responding to President Trump’s tariffs, Beijing blocked more American companies ...

Illumina shareholders received a warning shot. In response to President Trump’s initial tariff measures, the Chinese ...

GlobalData’s senior medical analyst says the ban will add to a downward trend for Illumina in the Chinese market.

Illumina on Monday lowered its annual forecast and said it plans to cut $100 million in spending after China announced a ban ...